65,437 trials
Diabetic Foot Ulcer
Primary: Adherence to Use of SmartMat — 6.4 number of foot scans/week
Ataxia Telangiectasia
Primary: Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS) — 0.94; 2.24 RmICARS score (0-29 points)
Lumbar Degenerative Disc Disease
Primary: Spinal Fusion Grade at 1 Year Via CT Scan — 1.67; 2.4 score on a scale
Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.18 Percentage-point of HbA1c
Hemianopia
Primary: Number of Points Detected at Multiple Locations — 14.0; 94.9; 63.6; 95.4 Number of points
Discrimination, Racial · Communication · Chronic Illness
Primary: 10-item Connor-Davidson Resilience Scale (CD-RISC) — 0.67; 0 average of number of units on a scale
Pulmonary Aspergillosis
Primary: Proportion of Participants Who Completed 12 Weeks of Therapy — 47; 23 Participants
Colitis, Ulcerative
Primary: Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score — 51.1; 43.5 percentage of participants
Brain Injuries, Traumatic · Sleep Initiation and Maintenance Disorders
Primary: Number of Participants With Adequate Data for Estimation of Dim Light Melatonin Onset (Self-Collected Saliva) — 7 Participants
Cystic Fibrosis
Primary: Sufficient Sputum Quantity for a Pellet — 9 Participants
Sleep · Physical Activity
Primary: Changes in Physical Activity — 8417.24; 8095.52; 9497.97 steps/day
HIV Infections · Pregnancy Related
Primary: Female Participants With Viral Suppression (<1,000 Copies/ml) — 82; 82 Participants — p=0.4
Motor Imagery
Primary: Kinematic Analysis: Change in Hip Flexion During Initial Contact. Baseline and 12 Weeks — -1.33; 5.1; 1.53 degrees
Non-small Cell Lung Cancer
Primary: Part 1: Overall Survival (OS) — 15.9; 20.1; 13.9 months — p=0.1782
Major Depressive Disorder
Primary: PHQ-9 Total Change From Baseline to Posttreatment: Experimental Group vs. Treatment as Usual Group — -1.941; -0.803 adjusted score change — p=0.0000022